Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

The nuclear receptor CAR (NR1I3) regulates serum triglyceride levels under conditions of metabolic stress.

Maglich JM, Lobe DC, Moore JT.

J Lipid Res. 2009 Mar;50(3):439-45. doi: 10.1194/jlr.M800226-JLR200. Epub 2008 Oct 21.

2.

Identification and characterization of a selective peroxisome proliferator-activated receptor beta/delta (NR1C2) antagonist.

Shearer BG, Steger DJ, Way JM, Stanley TB, Lobe DC, Grillot DA, Iannone MA, Lazar MA, Willson TM, Billin AN.

Mol Endocrinol. 2008 Feb;22(2):523-9. Epub 2007 Nov 1.

3.

Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist.

Sprecher DL, Massien C, Pearce G, Billin AN, Perlstein I, Willson TM, Hassall DG, Ancellin N, Patterson SD, Lobe DC, Johnson TG.

Arterioscler Thromb Vasc Biol. 2007 Feb;27(2):359-65. Epub 2006 Nov 16.

PMID:
17110604
4.

Identification of peptides that inhibit the DNA binding, trans-activator, and DNA replication functions of the human papillomavirus type 11 E2 protein.

Deng SJ, Pearce KH, Dixon EP, Hartley KA, Stanley TB, Lobe DC, Garvey EP, Kost TA, Petty RL, Rocque WJ, Alexander KA, Underwood MR.

J Virol. 2004 Mar;78(5):2637-41.

5.

The E1 helicase of human papillomavirus type 11 binds to the origin of replication with low sequence specificity.

Dixon EP, Pahel GL, Rocque WJ, Barnes JA, Lobe DC, Hanlon MH, Alexander KA, Chao SF, Lindley K, Phelps WC.

Virology. 2000 May 10;270(2):345-57.

6.

Replication-associated activities of purified human papillomavirus type 11 E1 helicase.

Rocque WJ, Porter DJ, Barnes JA, Dixon EP, Lobe DC, Su JL, Willard DH, Gaillard R, Condreay JP, Clay WC, Hoffman CR, Overton LK, Pahel G, Kost TA, Phelps WC.

Protein Expr Purif. 2000 Mar;18(2):148-59.

PMID:
10686145
7.

Molecular targets for human papillomaviruses: prospects for antiviral therapy.

Phelps WC, Barnes JA, Lobe DC.

Antivir Chem Chemother. 1998 Sep;9(5):359-77. Review.

PMID:
9875390
8.

Therapeutic evaluation of compounds in the SCID-RA papillomavirus model.

Lobe DC, Kreider JW, Phelps WC.

Antiviral Res. 1998 Dec;40(1-2):57-71.

PMID:
9864047
9.
10.
11.

Synergistic therapy by acyclovir and A1110U for mice orofacially infected with herpes simplex viruses.

Ellis MN, Lobe DC, Spector T.

Antimicrob Agents Chemother. 1989 Oct;33(10):1691-6.

12.

Orofacial infection of athymic mice with defined mixtures of acyclovir-susceptible and acyclovir-resistant herpes simplex virus type 1.

Ellis MN, Waters R, Hill EL, Lobe DC, Selleseth DW, Barry DW.

Antimicrob Agents Chemother. 1989 Mar;33(3):304-10.

13.

Induction of acyclovir-resistant mutants of herpes simplex virus type I in athymic nude mice.

Ellis MN, Martin JL, Lobe DC, Johnsrude JD, Barry DW.

J Antimicrob Chemother. 1986 Oct;18 Suppl B:95-101.

PMID:
3025159
14.

UV inactivation of pathogenic and indicator microorganisms.

Chang JC, Ossoff SF, Lobe DC, Dorfman MH, Dumais CM, Qualls RG, Johnson JD.

Appl Environ Microbiol. 1985 Jun;49(6):1361-5.

Supplemental Content

Support Center